Hims & Hers Health Inc. Aktie News

TD Cowen analysts estimate that the total addressable market for longevity healthcare exceeds $250 billion.

Hims & Hers remains attractive at $33, supported by renewed Novo Nordisk partnership and unique access to patient demand. Despite weak Q1 2026 results—4% revenue growth, declining margins, and a net loss—international expansion and diversified categories are strengthening the long-term outlook. Management targets $6.5B+ revenue and $1.3B+ adjusted EBITDA by 2030, with valuation justified if ret...

The Novo Nordisk partnership transformed Hims & Hers Health, Inc. from a fringe obesity player into an official healthcare ecosystem participant. Short interest remains elevated near 30%-32% of the HIMS float, leaving roughly 63 million shares vulnerable to further covering. HIMS management targets at least $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030 through platform exp...

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced Dr. Anant Vinjamoori is joining as the Chief Medical Officer of the Hims brand. As the company reimagines how everyone can access proactive, comprehensive care that helps them feel great, Dr. Vinjamoori will provide the clinical guidance that shapes the next phase of ...

Tech stocks are now facing the risk of AI disruption. REITs are benefiting from the AI Immunity Trade. Hard assets may become more valuable as AI advances.

TORONTO--(BUSINESS WIRE)--Hims & Hers Health, Inc. today announced the completion of its acquisition of Eucalyptus, the parent company of Juniper, marking the latest in a series of significant company investments in Canada. Since launching in 2025, Hims & Hers has already changed the game in Canada, becoming the first platform to bring generic semaglutide to eligible Canadians. By combining Jun...

BERLIN--(BUSINESS WIRE)--Hims & Hers Health, Inc. has completed its acquisition of Eucalyptus, the parent company of Juniper, advancing its position as the world's largest consumer health platform. In Germany, the closing strengthens Juniper's comprehensive, clinically rigorous, weight management offering with the technology, data, and infrastructure of Hims & Hers behind it. Since launching in...

TOKYO--(BUSINESS WIRE)--Hims & Hers Health, Inc. has completed its acquisition of Eucalyptus, the parent company of Juniper, marking a significant milestone in the company's global growth and its formal entry into Japan. This milestone puts the full weight of Hims & Hers' technology, data, and clinical infrastructure behind a platform that supports weight management care for people in Japan, a ...